The urinary incontinence market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006.

2008-05-19 21:35:47 - www.companiesandmarkets.com adds new report - Pipeline and Commercial Insight - Urinary Incontinence - Lifecycle management strategies retain mid-term market growth

www.companiesandmarkets.com/Summary-Market-Report/Pipeline-and-C ..

The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer''s Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK''s Vesicare (solifenacin), and Novartis'' Enablex (darifenacin).

Scope

Analysis of patient potential, unmet needs and clinical trial design in UI.
Overview of key marketed brands, late- and early-stage pipeline drugs, and cell therapies.
Indication-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs.
Identification of future market events that are expected to affect UI drug revenues.

Highlights

Pfizer''s Detrol LA (tolterodine) will remain the market leading UI brand through to 2012 when it comes off patent. At this point Detrol LA will be followed by the other second generation anticholinergics, GSK''s Vesicare (solifenacin), Novartis'' Enablex (darifenacin) and Pfizer''s chemical reformulation Toviaz (fesoterodine).

Following the patent expiry of the key brands, Detrol LA in 2012, and Enablex/Vesicare in 2015, a novel mechanism of action is required for long-term market growth. Examples of the possible mechanisms of action include the NK-1 antagonists and the adrenergic modulators.

Datamonitor has identified a great untapped patient base in the US stress urinary incontinence (SUI) market. A drug that could come into this market would benefit from exclusivity, being the only treatment approved for SUI in the US with a potential 28 million patient base.

Reasons to Purchase

Benchmark key late-stage UI pipeline compounds against current market leading brands.
Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
Understand unmet needs and opportunities in the UI market based on key opinion leader comments.

www.companiesandmarkets.com/Summary-Market-Report/Pipeline-and-C ..